Swiss National Bank Nurix Therapeutics, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 106,900 shares of NRIX stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,900

Previous 99,200 7.76%

Holding current value

$2.33 Million

Previous $2.07 Million 15.89%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$18.93 - $25.69 $145,761 - $197,813	7,700 Added 7.76%	106,900 $2.4 Million
Q2 2024 Aug 08, 2024	BUY	$12.02 - $21.3 $1.19 Million - $2.11 Million	99,200 New	99,200 $2.07 Million
Q3 2023 Nov 08, 2023	SELL	$7.86 - $10.08 $24,366 - $31,248	-3,100 Reduced 3.53%	84,800 $666,000
Q2 2023 Aug 09, 2023	BUY	$8.7 - $13.28 $100,919 - $154,048	11,600 Added 15.2%	87,900 $878,000
Q1 2023 May 10, 2023	SELL	$8.56 - $13.26 $76,184 - $118,014	-8,900 Reduced 10.45%	76,300 $677,000
Q4 2022 Feb 08, 2023	BUY	$9.86 - $14.59 $61,132 - $90,458	6,200 Added 7.85%	85,200 $935,000
Q2 2022 Aug 09, 2022	BUY	$7.88 - $14.82 $248,220 - $466,830	31,500 Added 66.32%	79,000 $1 Million
Q1 2022 May 09, 2022	BUY	$12.94 - $29.65 $45,290 - $103,775	3,500 Added 7.95%	47,500 $665,000
Q2 2021 Aug 06, 2021	BUY	$24.21 - $35.89 $462,411 - $685,499	19,100 Added 76.71%	44,000 $1.17 Million
Q1 2021 May 07, 2021	SELL	$26.98 - $50.17 $5,396 - $10,034	-200 Reduced 0.8%	24,900 $774,000
Q4 2020 Feb 05, 2021	BUY	$22.85 - $48.44 $573,535 - $1.22 Million	25,100 New	25,100 $825,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Nurix Therapeutics, Inc. Transaction History